A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

NCT05048719 · Completed

Last updated 2026-05-28

This study is testing the medication LY3502970 in adults with type 2 diabetes to see how it affects blood sugar levels compared to a placebo.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 383 people

Who can join Ages 18–75 · all sexes

Timeline Started 2021-09 · est. completion 2022-09

Where 44 sites · Hungary, Poland, Puerto Rico, Slovakia, United States

What this study is testing ClinicalTrials.gov NCT05048719 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.

Treatments tested

LY3502970 Drug

Administered orally
Dulaglutide Drug

Administered subcutaneously
Placebo Drug

Administered orally
Placebo Drug

Administered subcutaneously

Main thing measured	Change From Baseline in HbA1c in LY3502970 as Compared to Placebo
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05048719 ↗